Safety and efficacy of thalidomide in treatment of gastrointestinal bleeding secondary to angioectasias: a systematic review and meta-analysis

References

• DiGregorio AM, Alvey H. Gastrointestinal bleeding. [updated 2023 Jun 5]. In: statPearls [internet]. Treasure Island (FL): StatPearls Publishing; 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK537291/
   Google Scholar
• Iannone A, Principi M, Barone M, et al. Gastrointestinal bleeding from vascular malformations: is octreotide effective to rescue difficult-to-treat patients? Clin Res Hepatol Gastroenterol. 2016; 40(4):373–377. doi: 10.1016/j.clinre.2016.02.003.
   PubMed Web of Science ®Google Scholar
• Sami SS, Al-Araji SA, Ragunath K. Review article: gastrointestinal angiodysplasia - pathogenesis, diagnosis and management. Aliment Pharmacol Ther. 2014; 39(1):15–34. doi: 10.1111/apt.12527.
   PubMed Web of Science ®Google Scholar
• Sengupta N, Feuerstein JD, Jairath V, et al. Management of patients with acute lower gastrointestinal bleeding: an updated ACG guideline. Am J Gastroenterol. 2023; 118(2):208–231. doi: 10.14309/ajg.0000000000002130.
   PubMed Web of Science ®Google Scholar
• Fabian E, Königsbrügge O, Krejs GJ, et al. Review article: thalidomide for the management of gastrointestinal bleeding in a palliative care setting. Dig Dis. 2024;42(1):113–126. doi: 10.1159/000533437.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Moreau P, Terpos E, EHA Guidelines Committee. ESMO Guidelines Committee., et al. Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2021; Mar32(3):309–322. Electronic address: [email protected]; Electronic address: [email protected] doi: 10.1016/j.annonc.2020.11.014.
   PubMed Web of Science ®Google Scholar
• Thalidomide (marketed as Thalomid) Information. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/thalidomide-marketed-thalomid-information.
   Google Scholar
• Gkolfakis P, Fostier R, Tziatzios G, et al. Efficacy of pharmacologic treatment for treating gastrointestinal angiodysplasias-related bleeding: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2022;34(10):1021–1030. doi: 10.1097/MEG.0000000000002414.
   PubMed Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi: 10.1136/bmj.n71.
   PubMed Web of Science ®Google Scholar
• Review Manager. 5 (RevMan 5) [computer program]. version 5.4. Copenhagen: the Cochrane Collaboration, 2020.
   Google Scholar
• MedCalc Statistical Software version 19.1.3 (MedCalc Software bv. Ostend, Belgium; https://www.medcalc.org. 2019)
   Google Scholar
• Bayudan AM, Chen CH. Thalidomide for refractory gastrointestinal bleeding from vascular malformations in patients with significant comorbidities. WJCC. 2020;8(15):3218–3229. doi: 10.12998/wjcc.v8.i15.3218.
   PubMed Web of Science ®Google Scholar
• Chen H, Fu S, Feng N, et al. Bleeding recurrence in patients with gastrointestinal vascular malformation after thalidomide. Medicine (Baltimore. 2016;95(33):e4606.). doi: 10.1097/MD.0000000000004606.
   PubMed Web of Science ®Google Scholar
• Chen H, Wu S, Tang M, et al. Thalidomide for recurrent bleeding due to small-Intestinal angiodysplasia. N Engl J Med. 2023;389(18):1649–1659. doi: 10.1056/NEJMoa2303706.
   PubMed Web of Science ®Google Scholar
• Garrido A, Sayago M, López J, et al. Thalidomide in refractory bleeding due to gastrointestinal angiodysplasias. Rev Esp Enferm Dig. 2012;104(2):69–71. doi: 10.4321/S1130-01082012000200005.
   PubMed Web of Science ®Google Scholar
• Garrido Serrano A, León R, Sayago M, et al. Thalidomide treatment in cirrhotic patients with severe anemia secondary to vascular malformations. Dig Dis Sci. 2012; 57(4):1112–1113. doi: 10.1007/s10620-011-1971-9.
   PubMed Web of Science ®Google Scholar
• Ge ZZ, Chen HM, Gao YJ, et al. Efficacy of thalidomide for refractory gastrointestinal bleeding from vascular malformation. Gastroenterology. 2011;141(5):1629–1637.e4. e1-4. doi: 10.1053/j.gastro.2011.07.018.
   PubMed Web of Science ®Google Scholar
• Namdaran P, Zikos TA, Pan JY, et al. Thalidomide use reduces risk of refractory gastrointestinal bleeding in patients with continuous flow left ventricular assist devices. Asaio J. 2020; 66(6):645–651. doi: 10.1097/MAT.0000000000001054.
   PubMed Web of Science ®Google Scholar
• Awadie H, Zoabi A, Gralnek IM. Obscure-overt gastrointestinal bleeding: a review. Pol Arch Intern Med. 2022;132(5):16253. doi: 10.20452/pamw.16253.
   PubMedGoogle Scholar
• García-Compeán D, Del Cueto-Aguilera ÁN, Jiménez-Rodríguez AR, et al. Diagnostic and therapeutic challenges of gastrointestinal angiodysplasias: a critical review and view points. WJG. 2019;25(21):2549–2564. doi: 10.3748/wjg.v25.i21.2549.
   PubMed Web of Science ®Google Scholar
• Romagnuolo J, Brock AS, Ranney N. Is endoscopic therapy effective for angioectasia in obscure gastrointestinal bleeding?: a systematic review of the literature. J Clin Gastroenterol. 2015; 49(10):823–830. PMID: 25518005. doi: 10.1097/MCG.0000000000000266.
   PubMed Web of Science ®Google Scholar
• Rai D, Tariq R, Tahir MW, et al. Primary and secondary prevention strategies for gastrointestinal bleeding in patients with left ventricular assist device: a systematic review and network meta-analysis. Curr Probl Cardiol. 2021; 46(11):100835. doi: 10.1016/j.cpcardiol.2021.
   PubMed Web of Science ®Google Scholar